Painful bone metastases in hormone-refractory prostate cancer: Economic costs of strontium-89 and/or external radiotherapy

Urology

Volumn 50, Issue 5, 1997, Pages 747-753

  Malmberg, Irena ^b   Persson, Ulf ^b   Anders, Ask ^b   Tennvall, Jan ^b   Abrahamsson, Per Anders ^a  

^a LUND UNIVERSITY   (Sweden)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RADIOPHARMACEUTICAL AGENT; STRONTIUM 89;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; BONE METASTASIS; CANCER PAIN; CANCER RADIOTHERAPY; DRUG INDUCED DISEASE; FEMALE; HEALTH CARE COST; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RELAPSE; TREATMENT OUTCOME;

BONE NEOPLASMS; COST OF ILLNESS; COSTS AND COST ANALYSIS; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PAIN; PROSTATIC NEOPLASMS; STRONTIUM RADIOISOTOPES;

EID: 0030694829     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00326-9     Document Type: Article

References (16)

1. Wingo PA, Tong T, and Bolden S: Cancer statistics. CA Cancer J Clin 45: 8-30, 1995.
2. Esteve J, Kricker A, Ferlay J, and Parkiun DM (eds): Facts and Figures of Cancer in the European Community. Geneva, International Agency of Research on Cancer (World Health Organization), 1993.
3. Cancer Incidence in Sweden 1989. National Board of Health and Welfare. The Cancer Registry, 1990.
4. Payne R: Pain management in the patient with prostate cancer. Cancer 71(suppl 3): 1131-1137, 1993.
5. Nilsson S, and Westlin J-E: 89-Strontium treatment in prostatic cancer, in Pharmacological Treatment of Prostatic Cancer. Medical Products Agency, 1993, vol 3, pp 123-127.
6. Blake GM, Zivanovic MA, McEwan AJ, and Ackery DM: Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 12: 447-454, 1986.
7. Porter AT, and Reddy SM: Strontium 89 in the treatment of metastatic prostate cancer. Adv Oncol 11: 19-22, 1995.
8. Porter AT, McEwan AJ, Powe JE, Reid R, McGowan DG, and Lukka H: Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 25: 805-813, 1993.
9. Carlsson P, Hjertberg H, Jönsson B, and Varenhorst E: The cost of prostatic cancer in a defined population. Scand J Urol Nephrol 23: 93-96, 1989.
10. Hartunian NS, Smart CN, and Thomson MS: The Incidence and Economic Costs of Major Health Impairments. Toronto, Lexington Books, 1981, pp 133-192.
11. Drummond MF, Stoddard GL, and Torrance GW: Methods for the Economic Evaluation of Health Care Programmes. New York, Oxford University Press, 1987.
12. Wodinsky HB, and Jenkin RD: The cost of radiation treatment at an Ontario regional cancer center. Can Med Assoc J 137: 906-909, 1987.
13. Goddard M, and Hutton J: What is the cost of radiotherapy? Eur J Radiol 13: 76-79, 1991.
14. SBU, The Swedish Council on Technology Assessment in Health Care, Strålbehandling vid cancer. Stockholm, SBU, The Swedish Council on Technology Assessment in Health Care Report No. 129/1, 1996, pp 123-147.
15. 89SR-chloride) in patients with prostate cancer metastatic to bone. Nucl Med Commun 15: 499-504, 1994.
16. Quilty PM, Kirk D, Bolger JJ, Dearnaley DP, Lewington VJ, Mason MD, Reed NS, Russell JM, and Yardley J: A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer. Radiother Oncol 31: 33-40, 1994.